Pharmacokinetics of tildipirosin in pig tonsils

F. TORRES*
R. SANTAMARIA†
M. JIMENEZ‡
R. MENJÓN‡
A. IBANEZ‡
M. COLLELL§
L. AZLOR§ &
FRAILE*‡

*Departament de Producció Animal, ETSEA, University de Lleida, Lleida, Spain; †Technical Service MSD Animal Health, Madrid, Spain; ‡Marketing Manager MSD Animal Health, Madrid, Spain; §MSD Global Swine, Summit, NJ, USA; ‡Agrotecnio Center, Lleida, Spain

Torres, F., Santamaria, R., Jimenez, M., Menjón, R., Ibanez, A., Collell, M., Azlor, O., Fraile, L. Pharmacokinetics of tildipirosin in pig tonsils. J. vet. Pharmacol. Therap. doi: 10.1111/jvp.12258.

The penetration of antimicrobials in pig tonsils is hardly known. The objective of the study was to quantify the tildipirosin (TD) penetration in tonsils. Animals were randomly divided into six groups (control, T1, T2 (1), T2(5), T2(10), and T2(15)) of eight animals. T1 and T2 groups received a dose of 2 and 4 mg of TD/kg bw in one shot (Zuprevo® MSD Animal Health), respectively, and the control group received 2 mL of saline solution. The animals were sacrificed by intravenous administration of pentobarbital sodium 24 h after finishing the treatment for the control, T1, and T2(1) groups, whereas animals of T2(5), T2(10), and T2(15) groups were sacrificed at 5, 10, and 15 days, post-treatment, respectively. Tonsils and blood samples were taken at necropsy to obtain plasma, and the tildipirosin concentration was determined by high-performance liquid chromatography with tandem mass spectrometry detection. The concentration in plasma was always significantly lower than in tonsil. Average TD tonsil concentrations increased significantly in a dose-dependent manner, and the tonsil TD vs. plasma TD concentration ratio was approximately 75 for the doses of 2 and 4 mg of TD/kg bw at 24 h post-treatment. Moreover, the maximum concentration of tildipirosin in tonsil was observed at 1 day postadministration, and this concentration decreased gradually from this day until 15 days postadministration for the dose of 4 mg of TD/kg bw. Finally, the ratio AUCtonsil/AUCplasma was 97.9, and the T1/2 (h) was clearly higher in tonsil than in plasma.

(Paper received 15 December 2014; accepted for publication 13 July 2015)

Lorenzo Fraile, Departament de Producció Animal, ETSEA, University de Lleida, Lleida, Spain. E-mail: lorenzo.fraile@prodan.udl.cat

Tildipirosin (TD) is a semisynthetic tylosin analog, which has a unique chemical structure characterized by two piperidine substituents at C20 and C23, and a basic macycinone sugar moiety at C5 of the macrocyclic lactone ring that has been approved for the treatment for respiratory diseases in pigs and cattle (EMA, 2011). This macrolide is rapidly absorbed and extensively distributed to the site of respiratory infection. In lung, mean TD concentrations were characterized by a peak on day 1 and a slow decline until 17 days after administration (Rose et al., 2013). The long persistence of TD in the body is demonstrated further by a pronounced terminal elimination half-life of about 7 days in lung. As a class, the macrolides are characterized by extensive partitioning into tissues, where they achieve multifold higher concentrations relative to those observed in the blood plasma (Nightingale, 1997). The magnitude of the local accumulation and long persistence of TD in the lung results in a convenient treatment regimen (single administration) and positive clinical outcome rates for respiratory conditions (Rose et al., 2013).

One critical point in the epidemiology of Actinobacillus pleuropneumoniae (APP) is that pigs can become asymptomatic carriers of this micro-organism in their tonsils for long periods. In the literature, antimicrobial treatments have been used to eradicate APP from tonsils. Thus, Fittipaldi et al. (2005) used feed medicated with tilmicosin phosphate for 30 days but found that the tonsils of the majority of animals were APP PCR positive 30 days later. Other authors were also unable to eliminate this bacterium from tonsils (Angelet al., 2008) with the usual administration schedule recommended for tulathromycin (2.5 mg/kg bw/one shot). Finally, an eradication program that includes sow medication with enrofloxacin (a fluoroquinolone) seemed to be successful, but specific studies to demonstrate the presence or not of APP in tonsils were not performed (Baekbo, 2006). Thus, the goal of this study was to quantify the TD penetration in tonsils and to characterize its pharmacokinetic profile at the registered dose (4 mg of TD/kg bw) as a first step to check the potential use of this molecule to eradicate APP from tonsils in carrier animals.

Forty-eight 2-month-old clinically healthy hybrid pigs (Landrace × Large white) were selected for this study. Animals were randomly divided into six groups (control, T1, T2 (1), T2 (5), T2(10), and T2(15)) of eight animals. T1 and T2 groups
received a dose of 2 and 4 mg of TD/kg bw in one shot, respectively, and the control group received 2 mL of saline solution (NaCl 0.9%). Depending on the pig weight, the administration volume of 40 mg of TD/mL (Zuprevo®; MSD Animal Health) ranged from 0.75 to 1 and 1.5 to 2 mL for the 2 and 4 mg dose of TD/kg bw, respectively. All the treatments were administered intramuscularly in the neck. Groups were balanced by gender and weight. The animals were sacrificed by intravenous administration of pentobarbital sodium 24 h after finishing the treatment for the control, T1, and T2(1) groups, whereas animals of T2(5), T2(10), and T2(15) were sacrificed at 5, 10, and 15 days, post-treatment, respectively. Tonsils and blood samples were taken at necropsy to quantify the concentration of TD (Intervet Innovation GmbH, a member of the MSD Animal Health group in Schwabenheim, Germany). Briefly, these samples were assayed for TD using high-performance liquid chromatography (HPLC) with a Spark HySphere® C18 HD cartridge (Spark Holland B.V.) with tandem mass spectroscopy detection (LC/MS/MS) after solid-phase extraction (Online-SPE). Details of the extraction method ad phase mobile have been previously published (Rose et al., 2013). Quantitation of tildipirosin was performed using a standard curve consisting of eight concentrations ranging from 0.025 to 10 μg/mL (plasma) and 0.125 to 50 μg/g (tonsil homogenate) of tildipirosin. The lower limit of quantification (LLOQ) was 0.025 μg/mL (plasma) and 0.125 μg/g for tonsils.

Plasma and tonsil PK parameters were determined based on group mean values with a noncompartmental analysis using the computer program Pharsight WinNonlin® software version 5.1.1 and 5.2.1 (Pharsight Corporation, St. Louis, MO, USA). Area under the curve (AUC) of plasma and tonsil concentration vs. time (AUCplasma and AUCtonsil) was measured via a linear trapezoidal method with linear interpolation. The start of the terminal elimination phase was set to 24 h after administration as previously published (Rose et al., 2013). λz is defined as the first-order rate constant associated with the terminal (log-linear) portion of the curve, which is estimated by linear regression of time vs. logarithmic concentration. Finally, the terminal half-life (T1/2) was calculated as log2/λz.

All statistical analyses were carried out using R software (R Core Team, 2012) for these analyses, the individual pig was the experimental unit. The significance level (α) was set at 0.05. Shapiro–Wilk’s and Levene tests were used to evaluate the normality of the distribution of the variables and the homogeneity of variances, respectively. A nonparametric (Wilcoxon test) was chosen to compare the different TD concentration observed in plasma and tonsils between groups.

Average tildipirosin plasma (ATPC) and tonsil (ATTTC) concentration for the control, T1, and T2(1) group increased significantly (P < 0.05) in a dose-dependent manner, and the tonsil TD vs. plasma TD concentration ratio was approximately 75 at 24 h postadministration for the doses of 2 and 4 mg of TD/kg bw. On the other hand, the concentration in plasma was always significantly lower (P < 0.05) than in tonsil for the groups treated with 4 mg of TD/kg bw at 1, 5, 10, and 15 days post-treatment, whereas the maximum concentration of tildipirosin in tonsil was observed at 1 day postadministration with a gradual decrease until 15 days postadministration (Fig. 1). Moreover, the ratio AUCtonsil/AUCplasma was 97.9, and the T1/2 (h) was clearly higher in tonsil than in plasma (Table 1).

Tildipirosin exerts a positive role in the treatment and control of bovine and swine respiratory disease (EMA, 2011). This clinical efficacy can be explained by the extraordinary lung selectivity and concentration vs. time profile of this macrolide in pulmonary tissue (Rose et al., 2013). In the particular case to eliminate bacteria with antimicrobials from tonsils, the information generated in this study is necessary to know the pharmacokinetic profile of TD in tonsils because a similar pharmacokinetic profile cannot be assumed between airway compartments and tonsil. The concentration of tildipirosin in lung and bronchoalveolar lavage far exceeded plasma concentrations (Rose et al., 2013) as it has been also described for tulathromycin in pigs (Villarino et al., 2013a,b). The basic nature of the drug and a limited degree of ionization at physiological pH

Table 1. Tildipirosin concentrations and its pharmacokinetic parameters in tonsil and blood plasma (mean+SD) and its ratio thereof after single i.m administration of 40 mg/mL tildipirosin solution for injection at 4 mg of TD/kg bw

| Time after administration (hours) | Tonsil concentration (ng/g) | Plasmad concentration (ng/mL) | Ratio of tonsil vs. plasma |
|----------------------------------|-----------------------------|-------------------------------|--------------------------|
| 24                               | 3620 ± 386.3                | 48 ± 14                       | 75.4                     |
| 120                              | 2041.3 ± 740                | 20 ± 11                       | 102                      |
| 240                              | 1043.9 ± 292                | 11 ± 6                        | 95                       |
| 360                              | 590.1 ± 136                 | b.l.q.                        | n.a.                     |

Pharmacokinetic parameters (calculated from mean values)

| Parameter              | Value (ng/mL) | Value (ng/g) |
|------------------------|---------------|--------------|
| AUC_plasma (h-μg/g)    | 837.796       | 8.556        | 97.9 |
| λz (h)                 | 0.00235       | 0.00335      | 0.70 |
| T1/2 (h)               | 295           | 207          | 1.43 |

b.l.q. Below limit of quantification; n.a. Not applicable.
represent features that favor the distribution of the drug into extravascular compartments (Cox et al., 2010). The drug penetrated rapidly into the airways and tonsil, but concentration declined slowly. The drug concentration decay occurred faster in plasma than in the airways and tonsil. This result might indicate that different factors, other than/or in addition to simple drug diffusion, play a role in the process of movement of tildipirosin in and out between the plasma and the airway compartments and tonsils. The ratio TD tonsil vs. plasma concentration (75) is lower than the ratio TD lung vs. plasma concentration (83) at \( T_{\text{max}} \) (24 h postadministration) using a dose of 4 mg of TD/bw in one shot (Rose et al., 2013). In contrast, the ratio AUC_{tonsil}/AUC_{lung} is 93.5% although the AUC_{tonsil} could be overestimated due to the lack of tildipirosin determinations before 24 h postadministration. In any case, this result suggests that the exposure of the lung to this drug (Rose et al., 2013) is higher than the exposure at tonsil level.

Macrolides have been classified as time-dependent killing drugs, best described by the PK/PD parameter time above MIC (\( T > \text{MIC} \)). However, for newer macrolides such as tulathromycin, gamithromycin, and tilmicosin, the plasma AUC/MIC ratio appears to be the best correlate with successful outcome (Evans, 2005; Lees et al., 2006). In this case, the tildipirosin MIC_{90} for APP strains is 2 \( \mu \)g/mL (Rose et al., 2013). On the basis of tildipirosin concentration in tonsil and MIC_{90} for APP, the mean tonsil tildipirosin concentration is above the MIC_{90} for APP for about 5 days. However, this information is insufficient to predict whether the tonsil concentration is enough to eliminate this bacterium from this tissue and in \textit{in vivo} studies with carrier pigs are needed to confirm this assumption. The results from this study provide a good base to start working in this area.

ACKNOWLEDGMENT

The study was funded by MSD Animal Health.

REFERENCES

Angen, Ø., Andreasen, M., Nielsen, E.O., Stockmarr, A. & Baekbo, P. (2008) Effect of tulathromycin on the carrier status of \textit{Actinobacillus pleuropneumoniae} serotype 2 in the tonsils of pigs. \textit{Veterinary Record}, 163, 445–447.

Baekbo, P. (2006) Elimination of respiratory diseases – a Danish practitioners approach. \textit{Proceedings of the 19th IPVS Congress}, p. 313, 16–19 July, Copenhagen, Denmark. vol 1.

Cox, S.R., McLaughlin, C., Fielder, A.E., Yancey, M.F., Bowersock, T.L., García-Tapia, D., Bryson, L., Lucas, M.J., Robinson, J.A., Nanjiani, I. & Brown, S.A. (2010) Rapid and Prolonged distribution of tulathromycin into lung homogenate and pulmonary epithelial lining fluid of Holstein calves following a single subcutaneous administration of 2.5 mg/kg bodyweight. \textit{International Journal of Applied Research in Veterinary Medicine}, 8, 129–137.

EMA (2011) CVMP Assessment Report: Zuprevo (EMEA/V/C/002009). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/veterinary/002009/WC500106577.pdf (accessed 29 September 2011).

Evans, N.A. (2005) Tulathromycin: an overview of a new triamilide antibiotic for livestock respiratory disease. \textit{Veterinary Therapeutics}, 6, 83–95.

Fittipaldi, N., Klopstein, C., Gottschalk, M., Broes, A., Paradis, M.A. & Dick, C.P. (2005) Assessment of the efficacy of tilmicosin phosphate to eliminate \textit{Actinobacillus pleuropneumoniae} from carrier pigs. \textit{Canadian Journal of Veterinary Research}, 69, 146–150.

Lees, P., Concordet, D., Aliabadi, F.S. & Toutain, P.L. (2006) Drug selection and optimization of dosage schedules to minimize antimicrobial resistance. In \textit{Antimicrobial Resistance in Bacteria of Animal Origin Ed. Aarestrup, F.M., pp. 49–60. ASM Press, Washington, DC.}

Rose, M., Menge, M., Bohland, C., Zachiesche, E., Wilhelm, C., Klip, S., Metz, W., Allan, M., Röpke, R. & Nürnberg, M. (2013) Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of \textit{Actinobacillus pleuropneumoniae}. \textit{Journal Veterinary Pharmacology Therapeutics}, 36, 140–153.

Villarino, N., Lesman, S., Fielder, A., García-Tapia, D., Cox, S., Lucas, M., Robinson, J., Brown, S.A. & Martín-Jímenez, T. (2013a) Pulmonary pharmacokinetics of tulathromycin in swine. Part 2: intra-airway compartments. \textit{Journal of Veterinary Pharmacology and Therapeutics}, 36, 340–349.

Villarino, N., Lesman, S., Fielder, A., García-Tapia, D., Cox, S., Lucas, M., Robinson, J., Brown, S.A. & Martín-Jímenez, T. (2013b) Pulmonary pharmacokinetics of tulathromycin in swine. Part I: lung homogenate in healthy pigs and pigs challenged intra-tracheally with lipopolysaccharide of \textit{Escherichia coli}. \textit{Journal of Veterinary Pharmacology and Therapeutics}, 36, 329–339.
Dear Author,

During the copy-editing of your paper, the following queries arose. Please respond to these by marking up your proofs with the necessary changes/additions. Please write your answers on the query sheet if there is insufficient space on the page proofs. Please write clearly and follow the conventions shown on the attached corrections sheet. If returning the proof by fax do not write too close to the paper’s edge. Please remember that illegible mark-ups may delay publication.

Many thanks for your assistance.

| Query reference | Query                                                                 | Remarks |
|-----------------|----------------------------------------------------------------------|---------|
| 1               | AUTHOR: Please check that all the information displayed in your figure and table are displayed correctly and that they appear in the correct order. |         |
| 2               | AUTHOR: A running head short title was not supplied; please check if this one is suitable and, if not, please supply a short title of up to 40 characters that can be used instead. |         |
| 3               | AUTHOR: Please confirm that given names (red) and surnames/family names (green) have been identified correctly. |         |
| 4               | AUTHOR: Please make sure that all author names and affiliations spelt correctly. |         |
| 5               | AUTHOR: Please check the inserted address details and also provide full postal address for the corresponding author. |         |
| 6               | AUTHOR: Nightingale, 1997 has not been included in the Reference List, please supply full publication details. |         |
| 7               | AUTHOR: Please give address information for Spark Holland B.V.: town, state (if applicable), and country. |         |
| 8               | AUTHOR: R Core Team, 2012 has not been included in the Reference List, please supply full publication details. |         |
| 9               | AUTHOR: Please check this website address and confirm that it is correct. (Please note that it is the responsibility of the author(s) to ensure that all URLs given in this article are correct and useable.) |         |
| 10              | AUTHOR: Villarino et al. (2013a) has not been cited in the text. Please indicate where it should be cited: or delete from the Reference List. |         |
| 11              | AUTHOR: Villarino et al. (2013b) has not been cited in the text. Please indicate where it should be cited: or delete from the Reference List. |         |